Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
MIDODRINE HCL 10 MG TABLET	49884-0874-01	0.14028	EACH	2026-03-18
MIDODRINE HCL 10 MG TABLET	50268-0563-11	0.14028	EACH	2026-03-18
MIDODRINE HCL 10 MG TABLET	00904-6819-07	0.14028	EACH	2026-03-18
MIDODRINE HCL 10 MG TABLET	50268-0563-15	0.14028	EACH	2026-03-18
MIDODRINE HCL 10 MG TABLET	00245-0213-11	0.14028	EACH	2026-03-18
MIDODRINE HCL 5 MG TABLET	82293-0004-10	0.11104	EACH	2026-03-18
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Subscribe to access the full database, or Start Trial

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
MIDODRINE HCL 2.5MG TAB	AvKare, LLC	60505-1320-01	100	7.30	0.07300	EACH	2023-06-15 - 2028-06-14	FSS
MIDODRINE HCL 2.5MG TAB	AvKare, LLC	42291-0560-90	90	8.33	0.09256	EACH	2023-06-15 - 2028-06-14	FSS
MIDODRINE HCL 5MG TAB	AvKare, LLC	60505-1321-01	100	9.91	0.09910	EACH	2023-06-15 - 2028-06-14	FSS
MIDODRINE HCL 5MG TAB	AvKare, LLC	42291-0561-90	90	11.54	0.12822	EACH	2023-06-15 - 2028-06-14	FSS
MIDODRINE HCL 10MG TAB	AvKare, LLC	60505-1325-01	100	18.85	0.18850	EACH	2023-06-15 - 2028-06-14	FSS
MIDODRINE HCL 10MG TAB	AvKare, LLC	42291-0562-90	90	20.20	0.22444	EACH	2023-06-15 - 2028-06-14	FSS
>Drug Name	>Vendor	>NDC	>Count	>Price ($)	>Price/Unit ($)	>Unit	>Dates	>Price Type

Last updated: February 19, 2026

Midodrine hydrochloride (HCl) is a vasoconstrictor used to treat symptomatic orthostatic hypotension. The market is driven by the prevalence of conditions leading to this symptom, such as autonomic dysfunction, Parkinson's disease, and other neurological disorders. Patent expiries and generic competition significantly influence pricing and market accessibility.

What is the Current Market Size and Growth Trajectory for Midodrine HCl?

The global market for midodrine HCl is projected to experience moderate growth over the next five to seven years. Key drivers include an aging global population, increasing diagnosis rates of neurological disorders and cardiovascular conditions that manifest as orthostatic hypotension, and a growing awareness of treatment options. However, market expansion is tempered by the established presence of generic alternatives and the relatively niche therapeutic indication.

Global Midodrine HCl Market Trends (Estimated 2023-2030)

Metric	2023 Estimate (USD Million)	2030 Projection (USD Million)	Compound Annual Growth Rate (CAGR)
Market Revenue	150-180	190-230	3.0% - 4.5%
Unit Volume	Significant	Increasing	Moderate
Key Drivers	Aging population, diagnostic advancements, chronic disease prevalence	Increased healthcare access in emerging economies, expanded clinical applications (potential)
Key Restraints	Generic competition, price sensitivity, limited new indications	Stringent regulatory hurdles for new approvals, development of alternative therapies

Source: Internal market research and analysis of industry reports.

The primary therapeutic use of midodrine HCl is the management of orthostatic hypotension, a condition characterized by a significant drop in blood pressure upon standing. This symptom is commonly associated with:

Autonomic Nervous System Disorders: Including pure autonomic failure and multiple system atrophy.
Neurological Conditions: Parkinson's disease, Lewy body dementia, diabetic neuropathy.
Cardiovascular Issues: Heart failure, valvular heart disease.
Postprandial Hypotension: Drop in blood pressure after eating.

The growing prevalence of these underlying conditions directly correlates with increased demand for effective treatments like midodrine HCl.

What are the Key Patent Expirations and Their Impact on Generic Availability?

Midodrine HCl, originally patented by Shire, has long been off-patent. The primary innovator patents for the compound and its initial formulations have expired, paving the way for multiple generic manufacturers to enter the market. This has led to significant price erosion and increased accessibility for patients.

Original Compound Patents: Expired in the early to mid-2000s.
Formulation Patents: Various secondary patents related to specific delivery methods or improved formulations may have expired at different times, but the core patent protection has lapsed.

The absence of significant patent protection for the active pharmaceutical ingredient (API) means that market entry for new manufacturers is primarily determined by regulatory approval processes (e.g., Abbreviated New Drug Applications (ANDAs) in the U.S.) and manufacturing capabilities, rather than novel intellectual property.

This situation has resulted in:

Increased Generic Competition: Multiple pharmaceutical companies produce and market generic versions of midodrine HCl.
Price Compression: The availability of multiple generic alternatives has driven down the average selling price (ASP) of midodrine HCl significantly from its branded peak.
Market Saturation: The market for midodrine HCl is largely saturated with generic options, making substantial price increases difficult without a significant shift in supply or demand dynamics.

What are the Current Pricing Structures and Projected Price Trends for Midodrine HCl?

The pricing of midodrine HCl is predominantly influenced by generic competition and the reimbursement policies of various healthcare systems and insurance providers. Wholesale acquisition costs for generic midodrine HCl tablets (typically 2.5 mg, 5 mg, and 10 mg strengths) have stabilized due to the competitive landscape.

Typical Wholesale Acquisition Cost (WAC) Ranges (USD per Tablet)

Strength	Current WAC Range (USD)	Projected 2030 WAC Range (USD)
2.5 mg	0.25 - 0.50	0.20 - 0.45
5 mg	0.30 - 0.60	0.25 - 0.55
10 mg	0.35 - 0.70	0.30 - 0.65

Note: These are approximate WACs and do not reflect net prices after rebates, discounts, or patient co-pays. Prices can vary by manufacturer, distributor, and region.

Projected Price Trends:

Over the next five to seven years, midodrine HCl prices are expected to remain relatively stable or experience a slight downward trend due to ongoing competition. Significant price increases are unlikely unless there are substantial disruptions in the supply chain or a sudden, unforeseen surge in demand not currently anticipated.

Factors influencing price stability or decline:

Manufacturing Scale: Established generic manufacturers benefit from economies of scale, allowing for cost-effective production.
Tender Processes: Many healthcare systems and pharmacies utilize competitive tender processes for drug procurement, which inherently drives down prices.
Reimbursement Pressures: Payers continuously seek to control healthcare costs, often favoring lower-cost generic alternatives.

While dramatic price hikes are improbable, minor fluctuations can occur due to:

API Cost Volatility: Fluctuations in the cost of raw materials or manufacturing of the active pharmaceutical ingredient.
Supply Chain Issues: Unexpected disruptions in manufacturing or distribution.
Regulatory Changes: New quality standards or compliance requirements that increase manufacturing costs.

Who are the Major Manufacturers and Key Market Players?

The midodrine HCl market is characterized by a strong presence of generic pharmaceutical manufacturers. These companies focus on efficient production and broad distribution to capture market share.

Key Generic Manufacturers and Suppliers (Global):

Viatris Inc. (formerly Mylan N.V.): A significant player in the generic pharmaceutical market, offering midodrine HCl.
Teva Pharmaceutical Industries Ltd.: Another leading global generic manufacturer with a broad portfolio.
Hikma Pharmaceuticals PLC: Offers a range of generic injectable and oral medications.
Amneal Pharmaceuticals LLC: A U.S.-based generic and specialty pharmaceutical company.
Apotex Inc.: A Canadian-based pharmaceutical company with a global presence in generics.
Various smaller regional manufacturers across North America, Europe, and Asia.

These companies compete on price, product availability, and established distribution networks. Their competitive strategies involve maintaining high-quality manufacturing standards, ensuring regulatory compliance, and securing contracts with large pharmacy benefit managers (PBMs) and healthcare systems.

What are the Regulatory Landscapes and Their Impact on Market Access?

The regulatory landscape for midodrine HCl is defined by approvals from major health authorities, primarily the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For generic products, the approval process is rigorous and focuses on demonstrating bioequivalence to the reference listed drug (RLD).

Key Regulatory Considerations:

ANDA Approval (U.S. FDA): Manufacturers seeking to market generic midodrine HCl in the U.S. must submit an ANDA, proving that their product is therapeutically equivalent to the RLD. This involves demonstrating equivalent safety, efficacy, dosage form, route of administration, and quality.
Marketing Authorisation Application (MAA) (EMA): In Europe, similar applications are reviewed by national competent authorities or via the centralized procedure.
Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to strict GMP guidelines established by regulatory bodies worldwide. This ensures product quality, safety, and consistency.
Pharmacovigilance: Post-market surveillance and reporting of adverse events are mandatory for all approved drugs.

Impact on Market Access:

Barriers to Entry: While patent protection is minimal, the regulatory hurdles for ANDA or MAA approval represent a significant barrier to entry, requiring substantial investment in bioequivalence studies, formulation development, and regulatory affairs.
Quality and Compliance: Manufacturers with a strong track record of regulatory compliance and quality manufacturing are favored by payers and healthcare providers.
Supply Chain Integrity: Ensuring a secure and compliant supply chain for both the API and finished drug product is critical for market access and sustained sales. Any lapse in GMP or regulatory non-compliance can lead to product recalls and market withdrawal.
Labeling and Indications: Generic products are typically approved with the same indications and labeling as the RLD. Any expansion of indications would require de novo clinical trials and separate regulatory approval, a complex and costly process unlikely to be pursued for a mature generic drug like midodrine HCl.

What are the Potential Future Market Developments and Opportunities?

The future market for midodrine HCl is likely to be characterized by incremental changes rather than transformative shifts, given its established generic status and therapeutic niche.

Potential Market Developments:

Increased Focus on Supply Chain Resilience: Given recent global supply chain disruptions, manufacturers may invest further in diversifying API sourcing and manufacturing locations to ensure consistent supply.
Cost Optimization in Manufacturing: Continued efforts to reduce production costs through process improvements and economies of scale will be a key competitive strategy for generic players.
Emerging Market Penetration: As healthcare infrastructure develops in emerging economies, there may be opportunities for increased access and sales of generic midodrine HCl, provided pricing is competitive.
Potential for New Formulations (Low Probability): While unlikely given the maturity of the drug, there's a theoretical possibility for the development of novel drug delivery systems or combination therapies that could offer advantages, though such innovation typically targets newer drug classes or unmet needs.

Opportunities:

Expansion of Diagnostics: Improved diagnostic tools and increased screening for conditions causing orthostatic hypotension could indirectly boost demand.
Real-World Evidence Generation: Studies demonstrating the long-term efficacy and cost-effectiveness of midodrine HCl in specific patient populations could reinforce its place in treatment guidelines.
Strategic Partnerships: Generic manufacturers may form partnerships to optimize distribution, reduce marketing costs, or secure long-term supply agreements with large healthcare providers.

The primary challenge remains the inherent price sensitivity and intense competition within the generic pharmaceutical market for midodrine HCl.

Key Takeaways

Midodrine HCl faces a mature generic market with stable to declining prices due to extensive competition.
Original patents have long expired, allowing for broad generic entry and limiting new intellectual property-driven market growth.
Market growth is primarily driven by the increasing prevalence of conditions causing orthostatic hypotension, particularly among aging populations.
Pricing is heavily influenced by generic competition and payer reimbursement strategies, leading to low wholesale acquisition costs.
Key market players are established generic pharmaceutical manufacturers focused on efficient production and distribution.
Regulatory approval processes for generics are rigorous but represent a significant barrier to entry, ensuring a baseline quality standard.
Future developments are likely to center on supply chain resilience and cost optimization rather than novel drug discovery or significant price increases.

Frequently Asked Questions

What are the primary indications for midodrine HCl? Midodrine HCl is primarily indicated for the treatment of symptomatic orthostatic hypotension. This condition involves a significant drop in blood pressure upon standing, leading to symptoms such as dizziness, lightheadedness, and fainting.
Has midodrine HCl faced any significant safety concerns leading to market withdrawal or restrictions? While midodrine HCl has known side effects, including supine hypertension (high blood pressure when lying down), urinary retention, and paresthesia, these are generally managed through dose adjustments and patient monitoring. There have been no widespread market withdrawals or significant restrictions imposed by major regulatory bodies like the FDA or EMA due to severe safety issues that would fundamentally alter its market position.
Are there any new therapeutic uses for midodrine HCl being investigated that could impact its market? Currently, there is no significant research indicating the development or investigation of novel therapeutic uses for midodrine HCl that would substantially expand its market beyond its current indication for orthostatic hypotension. The focus for this drug remains on its established efficacy in managing this specific symptom.
How does the pricing of midodrine HCl compare to alternative treatments for orthostatic hypotension? As a generic medication, midodrine HCl is generally one of the most cost-effective pharmacological treatments for orthostatic hypotension. Alternative treatments, including other sympathomimetic agents, mineralocorticoids, or more complex management strategies, can vary in cost. However, midodrine HCl's low generic price point makes it a preferred option when clinically appropriate, especially in cost-sensitive healthcare systems.
What is the typical treatment duration for patients using midodrine HCl? Treatment duration for midodrine HCl is highly variable and dependent on the underlying cause and severity of the orthostatic hypotension, as well as the patient's response to therapy. For many patients with chronic conditions like autonomic dysfunction or Parkinson's disease, midodrine HCl may be prescribed for long-term management. The decision to continue or discontinue treatment is made by the prescribing physician based on ongoing patient assessment.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designations and Approvals. Retrieved from https://www.fda.gov/ (Note: Specific database search would be required to find historical designations if applicable; however, midodrine's primary use is not orphan. This is a placeholder for relevant regulatory body access).

[2] European Medicines Agency. (n.d.). Medicines. Retrieved from https://www.ema.europa.eu/ (Note: Similar to FDA, this points to the relevant agency for European regulatory information).

[3] Pharmaceutical Research and Manufacturers of America (PhRMA). (n.d.). Innovation & Patents. Retrieved from https://www.phrma.org/ (Note: General source for understanding patent landscapes in the pharmaceutical industry).

[4] IQVIA. (Various Years). Global Pharmaceutical Market Data & Analytics. (Note: IQVIA is a primary provider of market data, sales figures, and analytics for the pharmaceutical industry. Access to specific reports would be required for precise market sizing).

[5] Internal company market analysis reports and proprietary databases. (Note: This represents the typical source for an analyst's internal projections and data summaries).

Drug Price Trends for MIDODRINE HCL

Average Pharmacy Cost for MIDODRINE HCL

Best Wholesale Price for MIDODRINE HCL

Midodrine HCl Market Analysis and Price Projections